Table 2.
Demographics of patients with CTCs≥3/5 mL blood (n=136) and mCTC≥1/5 mL blood (n=120) used for analysis of PRL-3 and MMP9 expression and its association with clinicopathologic features.
| PRL-3 and MMP9 expression in CTCs | P value | PRL-3 and MMP9 expression in MCTC | P value | |||
|---|---|---|---|---|---|---|
| Characteristics | Negative | Positive | Negative | Positive | ||
| Gender | ||||||
| Male | 23 | 61 | 0.415 | 16 | 61 | 0.548 |
| Female | 11 | 41 | 7 | 36 | ||
| Depth of invasion | ||||||
| T1–T3 | 23 | 67 | 0.834 | 15 | 67 | 0.721 |
| T4 | 11 | 35 | 8 | 30 | ||
| Lymphatic metastasis | ||||||
| No | 18 | 46 | 0.427 | 11 | 41 | 0.629 |
| Yes | 16 | 56 | 12 | 56 | ||
| Distant metastasis | ||||||
| No | 29 | 72 | 0.089 | 21 | 67 | 0.030 |
| Yes | 5 | 30 | 2 | 30 | ||
| TNM stage | ||||||
| I+II | 16 | 33 | 0.122 | 11 | 20 | 0.070 |
| III+IV | 18 | 69 | 12 | 77 | ||